A Multicenter, Double-Blind, Phase II Clinical Trial To Evaluate Efficacy And Safety Of Levophencynonate Hydrochloride In Patient With Vertigo Caused By Posterior Circulation Infarction

Trial Profile

A Multicenter, Double-Blind, Phase II Clinical Trial To Evaluate Efficacy And Safety Of Levophencynonate Hydrochloride In Patient With Vertigo Caused By Posterior Circulation Infarction

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2016

At a glance

  • Drugs Levophencynonate (Primary)
  • Indications Vertigo
  • Focus Therapeutic Use
  • Sponsors Sihuan Pharmaceutical Holdings Group
  • Most Recent Events

    • 14 Apr 2016 The primary endpoint time frame has been changed from 14 days to 7 days
    • 14 Apr 2016 Status changed from recruiting to completed.
    • 01 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top